Acumen Pharmaceuticals (NASDAQ:ABOS – Get Rating) and Immunovant (NASDAQ:IMVT – Get Rating) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Risk & Volatility

Acumen Pharmaceuticals has a beta of -1.92, meaning that its stock price is 292% less volatile than the S&P 500. Comparatively, Immunovant has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500.

Profitability

This table compares Acumen Pharmaceuticals and Immunovant's net margins, return on equity and return on assets.

Analyst Ratings

Acumen Pharmaceuticals presently has a consensus target price of $17.67, suggesting a potential upside of 200.97%. Immunovant has a consensus target price of $16.86, suggesting a potential downside of 8.73%. Given Acumen Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Acumen Pharmaceuticals is more favorable than Immunovant.

Earnings and Valuation

This table compares Acumen Pharmaceuticals and Immunovant's gross revenue, earnings per share and valuation.

Acumen Pharmaceuticals has higher revenue and earnings than Immunovant.

Insider and Institutional Ownership

67.9% of Acumen Pharmaceuticals shares are held by institutional investors. Comparatively, 32.8% of Immunovant shares are held by institutional investors. 4.7% of Acumen Pharmaceuticals shares are held by insiders. Comparatively, 3.0% of Immunovant shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Acumen Pharmaceuticals beats Immunovant on 8 of the 10 factors compared between the two stocks.

About Acumen Pharmaceuticals

(Get Rating)

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

About Immunovant

(Get Rating)

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Receive News & Ratings for Acumen Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acumen Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.